Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial

Autor: Wulf, Gerald G, Altmann, Bettina, Ziepert, Marita, D'Amore, Francesco, Held, Gerhard, Greil, Richard, Tournilhac, Olivier, Relander, Thomas, Viardot, Andreas, Wilhelm, Martin, Wilhelm, Christian, Pezzutto, Antonio, Zijlstra, Josee M, Van Den Neste, Eric, Lugtenburg, Pieternella J, Doorduijn, Jeanette K, Gelder, Michel van, van Imhoff, Gustaaf W, Zettl, Florian, Braulke, Friederike, Nickelsen, Maike, Glass, Bertram, Rosenwald, Andreas, Gaulard, Philippe, Loeffler, Markus, Pfreundschuh, Michael, Schmitz, Norbert, Trümper, Lorenz, ACT-2 study investigators
Přispěvatelé: UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Hematology, CCA - Cancer Treatment and quality of life, Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Hematologie (9)
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Male
cd52 expression
Cancer Research
epstein-barr-virus
medicine.medical_treatment
CHOP
Gastroenterology
PROPHYLAXIS
0302 clinical medicine
Cause of Death
Antineoplastic Combined Chemotherapy Protocols
Medicine
Significant risk
Alemtuzumab
ComputingMilieux_MISCELLANEOUS
Aged
80 and over
Hematology
lymphoproliferative disorders
Hazard ratio
[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology
Middle Aged
CHEMOTHERAPY
Prognosis
3. Good health
Treatment Outcome
Oncology
Vincristine
030220 oncology & carcinogenesis
Toxicity
PHASE-II
Female
medicine.drug
medicine.medical_specialty
prognostic-factors
Medication Adherence
03 medical and health sciences
SDG 3 - Good Health and Well-being
Internal medicine
Humans
non-hodgkin-lymphoma
Cyclophosphamide
Aged
Chemotherapy
therapy
business.industry
Lymphoma
T-Cell
Peripheral
DETUDE-DES-LYMPHOMES
medicine.disease
Survival Analysis
Peripheral T-cell lymphoma
030104 developmental biology
Doxorubicin
Prednisone
business
Zdroj: Leukemia, Vol. 35, no.1, p. 143-155 (2021)
Wulf, G G, Altmann, B, Ziepert, M, D’Amore, F, Held, G, Greil, R, Tournilhac, O, Relander, T, Viardot, A, Wilhelm, M, Wilhelm, C, Pezzutto, A, Zijlstra, J M, Neste, E V D, Lugtenburg, P J, Doorduijn, J K, Gelder, M V, van Imhoff, G W, Zettl, F, Braulke, F, Nickelsen, M, Glass, B, Rosenwald, A, Gaulard, P, Loeffler, M, Pfreundschuh, M, Schmitz, N, Trümper, L & ACT-2 study investigators 2021, ' Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma : the DSHNHL2006-1B/ACT-2 trial ', Leukemia, vol. 35, no. 1, pp. 143-155 . https://doi.org/10.1038/s41375-020-0838-5
Leukemia, 35(1), 143-155. Nature Publishing Group
Leukemia
Leukemia, Springer Nature, 2021, 35 (1), pp.143-155. ⟨10.1038/s41375-020-0838-5⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, 35 (1), pp.143-155. ⟨10.1038/s41375-020-0838-5⟩
Leukemia, 143-155. Nature Publishing Group
ISSUE=1;STARTPAGE=143;ENDPAGE=155;ISSN=0887-6924;TITLE=Leukemia
Wulf, G G, Altmann, B, Ziepert, M, D’Amore, F, Held, G, Greil, R, Tournilhac, O, Relander, T, Viardot, A, Wilhelm, M, Wilhelm, C, Pezzutto, A, Zijlstra, J M, Neste, E V D, Lugtenburg, P J, Doorduijn, J K, Gelder, M V, van Imhoff, G W, Zettl, F, Braulke, F, Nickelsen, M, Glass, B, Rosenwald, A, Gaulard, P, Loeffler, M, Pfreundschuh, M, Schmitz, N, Trümper, L & for the ACT-2 study investigators 2021, ' Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma : the DSHNHL2006-1B/ACT-2 trial ', Leukemia, vol. 35, no. 1, pp. 143-155 . https://doi.org/10.1038/s41375-020-0838-5
ISSN: 0887-6924
1476-5551
DOI: 10.1038/s41375-020-0838-5
Popis: PTCL patients exhibit poor survival with existing treatments. We investigated the efficacy of CHOP combined with alemtuzumab in 116 PTCL patients age 61–80 in an open-label, randomized phase 3 trial. Alemtuzumab was given on day 1, to a total of 360 mg in 21 patients, or 120 mg in 37. Hematotoxicity was increased with A-CHOP resulting in more grade ≥3 infections (40% versus 21%) and 4 versus 1 death due to infections, respectively. CR/CRu rate was 60% for A-CHOP and 43% for CHOP, and OR rate was 72% and 66%, respectively. Three-year-EFS, PFS and OS were 27% [15%–39%], 28% [15%–40%], and 37% ([23%–50%] for A-CHOP, and 24% [12%–35%], 29% [17%–41%], and 56% [44%–69%] for CHOP, respectively, showing no significant differences. Multivariate analyses, adjusted for strata and sex confirmed these results (hazard ratio HREFS: 0.7 ([95% CI: 0.5–1.1]; p = 0.094), HRPFS: 0.8 ([95% CI: 0.5–1.2]; p = 0.271), HROS: 1.4 ([95% CI: 0.9–2.4]; p = 0.154). The IPI score was validated, and male sex (HREFS 2.5) and bulky disease (HREFS 2.2) were significant risk factors for EFS, PFS, and OS. Alemtuzumab added to CHOP increased response rates, but did not improve survival due to treatment-related toxicity.
Databáze: OpenAIRE
Externí odkaz: